Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$282.00
+1.7%
$314.19
$261.59
$431.79
$8.04B0.94206,996 shs235,140 shs
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.77
-2.8%
$2.44
$1.64
$2.99
$1.06B1.113.03 million shs2.76 million shs
Concordia International Corp. stock logo
CXR
Concordia International
C$25.04
C$19.02
C$417.00
C$1.22BN/A4,054 shs73,541 shs
Genius Group Limited stock logo
GNS
Genius Group
$0.39
+5.3%
$0.00
$0.24
$2.48
$29.13M11.975.41 million shs2.78 million shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+3.37%-0.72%-18.34%-14.76%-24.17%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%+1.59%
Cronos Group Inc. stock logo
CRON
Cronos Group
+10.47%+7.14%+6.74%+28.96%+51.60%
Concordia International Corp. stock logo
CXR
Concordia International
0.00%0.00%0.00%0.00%0.00%
Genius Group Limited stock logo
GNS
Genius Group
0.00%0.00%0.00%0.00%-69.06%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6959 of 5 stars
3.43.00.04.22.53.31.9
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
0.4375 of 5 stars
1.23.00.00.02.30.01.3
Concordia International Corp. stock logo
CXR
Concordia International
N/AN/AN/AN/AN/AN/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$461.0063.48% Upside
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
2.33
Hold$2.832.29% Upside
Concordia International Corp. stock logo
CXR
Concordia International
N/AN/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/A

Current Analyst Ratings

Latest BLU, CRON, GNS, CXR, and BIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$420.00 ➝ $385.00
4/8/2024
Cronos Group Inc. stock logo
CRON
Cronos Group
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$2.00 ➝ $2.50
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B3.01$12.20 per share23.12$306.51 per share0.92
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
Cronos Group Inc. stock logo
CRON
Cronos Group
$87.24M12.13N/AN/A$2.87 per share0.97
Concordia International Corp. stock logo
CXR
Concordia International
C$569.62M0.00N/A5.85C$6.08 per share0.00
Genius Group Limited stock logo
GNS
Genius Group
$18.19M1.60N/AN/A$0.50 per share0.79

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A24.61N/A-23.86%3.90%2.77%8/1/2024 (Estimated)
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
Cronos Group Inc. stock logo
CRON
Cronos Group
-$73.96M-$0.19N/A92.33N/A-84.15%-3.99%-3.87%8/13/2024 (Estimated)
Concordia International Corp. stock logo
CXR
Concordia International
N/AC$351.680.07N/AN/AN/AN/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
-$55.05MN/A0.00N/AN/AN/AN/AN/A

Latest BLU, CRON, GNS, CXR, and BIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Cronos Group Inc. stock logo
CRON
Cronos Group
-$0.01-$0.01N/A-$0.01$24.30 million$25.29 million      
5/7/2024Q1 2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.04$2.29+$0.25-$8.87$619.09 million$610.82 million    
2/29/2024Q4 2023
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A-$0.05-$0.05$0.02$25.15 million$23.92 million    
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
N/AN/AN/AN/AN/A
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
22.54
21.81
Concordia International Corp. stock logo
CXR
Concordia International
457.02
2.10
1.66
Genius Group Limited stock logo
GNS
Genius Group
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Concordia International Corp. stock logo
CXR
Concordia International
N/A
Genius Group Limited stock logo
GNS
Genius Group
14.28%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.50%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
Cronos Group Inc. stock logo
CRON
Cronos Group
1.96%
Concordia International Corp. stock logo
CXR
Concordia International
N/A
Genius Group Limited stock logo
GNS
Genius Group
51.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.53 millionOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
Cronos Group Inc. stock logo
CRON
Cronos Group
356382.01 million374.52 millionOptionable
Concordia International Corp. stock logo
CXR
Concordia International
N/A48.91 millionN/ANot Optionable
Genius Group Limited stock logo
GNS
Genius Group
47573.87 million36.06 millionNot Optionable

BLU, CRON, GNS, CXR, and BIO Headlines

SourceHeadline
Genius Sports jumps after revenue beat, full-year guidance liftGenius Sports jumps after revenue beat, full-year guidance lift
seekingalpha.com - May 8 at 8:15 AM
Genius Group to Present at the Sidoti Micro Cap ConferenceGenius Group to Present at the Sidoti Micro Cap Conference
globenewswire.com - May 3 at 10:30 AM
Genius Group Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication ProgramGenius Group Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
globenewswire.com - May 3 at 10:00 AM
Genius Group adds Alan Turing AI Avatar to C-Suite of Avatars as it disrupts education modelGenius Group adds Alan Turing AI Avatar to C-Suite of Avatars as it disrupts education model
finance.yahoo.com - May 1 at 1:24 PM
GNS Stock: Genius Group Gives an AI of Alan Turing a Seat in the C-SuiteGNS Stock: Genius Group Gives an AI of Alan Turing a Seat in the C-Suite
investorplace.com - April 30 at 3:09 PM
Genius Group Limited (NYSEAMERICAN:GNS) Sees Large Drop in Short InterestGenius Group Limited (NYSEAMERICAN:GNS) Sees Large Drop in Short Interest
americanbankingnews.com - April 30 at 4:12 AM
Leading Education Entrepreneurs join Genius Group as New ShareholdersLeading Education Entrepreneurs join Genius Group as New Shareholders
globenewswire.com - April 26 at 8:00 AM
Genius Group Appoints Alan Turing AI as Chief AI OfficerGenius Group Appoints Alan Turing AI as Chief AI Officer
globenewswire.com - April 24 at 7:00 AM
Amazon launches genius new subscription productAmazon launches genius new subscription product
msn.com - April 23 at 9:21 PM
Genius Group Appoints Leading Edtech Investor Michael Moe as Board ChairmanGenius Group Appoints Leading Edtech Investor Michael Moe as Board Chairman
globenewswire.com - April 19 at 12:00 PM
Genius Group Launches Its First Sovereign AI Education Ecosystem: DetailsGenius Group Launches Its First Sovereign AI Education Ecosystem: Details
msn.com - April 12 at 2:07 PM
Genius Group Launches Genius City Singapore: Companys 1st Sovereign AI Education EcosystemGenius Group Launches Genius City Singapore: Company's 1st Sovereign AI Education Ecosystem
globenewswire.com - April 12 at 8:00 AM
Genius Group launches AI Avatar Toolkit for Global Faculty to build their own AI TutorsGenius Group launches AI Avatar Toolkit for Global Faculty to build their own AI Tutors
globenewswire.com - April 5 at 8:00 AM
Genius Group announces the appointment of Mr. Adrian Reese as Chief Financial OfficerGenius Group announces the appointment of Mr. Adrian Reese as Chief Financial Officer
markets.businessinsider.com - March 26 at 12:32 PM
Genius Group announces the appointment of Mr. Adrian Reese as Chief Financial OfficerGenius Group announces the appointment of Mr. Adrian Reese as Chief Financial Officer
finance.yahoo.com - March 26 at 12:32 PM
Whats Going On With Edtech Company Genius Shares Today?What's Going On With Edtech Company Genius Shares Today?
msn.com - March 22 at 9:52 AM
Genius Group Updated 2024 Financial Guidance: $105 million to $110 million revenue with $6.0 million to $7.0 million positive EBITDAGenius Group Updated 2024 Financial Guidance: $105 million to $110 million revenue with $6.0 million to $7.0 million positive EBITDA
globenewswire.com - March 21 at 5:00 PM
Toby Keith Elected Into Country Music Hall of Fame, in Voting That Wrapped Up Days Before His DeathToby Keith Elected Into Country Music Hall of Fame, in Voting That Wrapped Up Days Before His Death
nz.finance.yahoo.com - March 18 at 3:41 PM
Genius Group announces merger with OpenExOGenius Group announces merger with OpenExO
msn.com - March 18 at 3:41 PM
Genius Group and OpenExO Sign Merger Agreement, Accelerating Plans to Build Global AI Education GroupGenius Group and OpenExO Sign Merger Agreement, Accelerating Plans to Build Global AI Education Group
globenewswire.com - March 18 at 1:00 PM
Genius Group Limited: Genius Group Release Additional Details of FatBrain AI TransactionGenius Group Limited: Genius Group Release Additional Details of FatBrain AI Transaction
finanznachrichten.de - March 18 at 10:40 AM
Genius Group Release Additional Details of FatBrain AI TransactionGenius Group Release Additional Details of FatBrain AI Transaction
globenewswire.com - March 18 at 7:00 AM
Genius Group to Host Genius Investor Call on 21 March, 2024 Providing Revised Post-merger 2024 Guidance and RoadmapGenius Group to Host Genius Investor Call on 21 March, 2024 Providing Revised Post-merger 2024 Guidance and Roadmap
globenewswire.com - March 15 at 3:35 PM
Genius Group Limited: Genius Group Completes FatBrain AI Merger, 150% Increase in 2023 Combined Proforma Revenue GuidanceGenius Group Limited: Genius Group Completes FatBrain AI Merger, 150% Increase in 2023 Combined Proforma Revenue Guidance
finanznachrichten.de - March 15 at 5:54 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
BELLUS Health logo

BELLUS Health

NASDAQ:BLU
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
Cronos Group logo

Cronos Group

NASDAQ:CRON
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Concordia International logo

Concordia International

TSE:CXR
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Genius Group logo

Genius Group

NYSEAMERICAN:GNS
Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.